Autoimmune Hemolytic Anemia Therapeutics Market to Record a CAGR of 9.1%, Majority of Market Growth to Originate from North America - Technavio

NEW YORK, Oct. 6, 2022 /PRNewswire/ -- The autoimmune hemolytic anemia therapeutics market has been segmented by product (corticosteroids, monoclonal antibodies, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). North America will account for 52% of the market's growth during the forecast period. This growth is attributed to factors such as patient assistance programs and regulatory incentives that provide financial incentives and development assistance to pharmaceutical companies for the development of novel drugs. The US and Canada are the key countries for the autoimmune hemolytic anemia therapeutics market in North America.

The autoimmune hemolytic anemia therapeutics market size is expected to grow by USD 268.22 million from 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 9.1% during the forecast period, according to Technavio.

Find a comprehensive report summary describing the market size and forecast along with research methodology. The FREE sample report is available in PDF format

By product, the corticosteroids segment will be the largest contributor to market growth during the forecast period. The growth of this segment is driven by factors such as the strong therapeutic value of corticosteroids. Corticosteroids lower the production of autoantibodies by B-cells. In addition, they reduce the density of Fc-gamma receptors on phagocytes in the spleen. They also have the ability to induce partial remission in most patients. However, corticosteroids have various side effects. In some patients, they are entirely contraindicated with comorbidities, including uncontrolled hypertension, obesity, diabetes, and osteoporosis. Combination therapy of corticosteroids with azathioprine or cyclophosphamide is used to minimize the complications.

Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a FREE PDF Sample Report

Regulatory incentives are driving the autoimmune hemolytic anemia therapeutics market. Autoimmune hemolytic anemia is a rare blood disorder. For instance, the global prevalence of autoimmune hemolytic anemia is approximately 0.02%. In Western Europe and North America, the annual incidence of this disease is estimated to be 0.003%. However, there is a lack of therapeutics for autoimmune hemolytic anemia due to low profits and expensive research. Hence, regulatory authorities are granting special drug designations, such as orphan drug designation, which provides development assistance and financial incentives to vendors.

The R&D of novel therapeutics is a key trend in the market. There is a limited number of approved drugs in the autoimmune hemolytic anemia therapeutics market. As a result, there is a high demand for treatment options in the market. Hence, various pharmaceutical and biotechnology companies are initiating the R&D of novel therapeutics. The drugs under development have high safety and efficacy profiles, which is expected to accelerate the approval of these therapeutics during the forecast period. Thus, expected new approvals and the development of novel therapeutics will contribute to the growth of the market during the forecast period.

Identify key trends, drivers, and challenges in the market, which will help vendors improve their strategies to stay ahead of their competitors. View our FREE PDF Sample Report

Renal Anemia Therapeutics Market by Application and Geography - Forecast and Analysis 2022-2026: The renal anemia therapeutics market share is expected to increase by USD 1.97 billion from 2021 to 2026.

Blood Market by Product and Geography - Forecast and Analysis 2022-2026: The blood market share is expected to increase by USD 1.82 billion from 2021 to 2026.

Browse Health Care Market Reports

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026 
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary 
• Exhibit 17: Five forces analysis - Comparison between2021 and 2026

• 4.2 Bargaining power of buyers 
• Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026

• 4.3 Bargaining power of suppliers 
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants 
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes 
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry 
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition 
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Product

• 5.1 Market segments 
• Exhibit 24: Chart on Product - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Product - Market share 2021-2026 (%)

• 5.2 Comparison by Product 
• Exhibit 26: Chart on Comparison by Product
• Exhibit 27: Data Table on Comparison by Product

• 5.3 Corticosteroids - Market size and forecast 2021-2026
• Exhibit 28: Chart on Corticosteroids - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on Corticosteroids - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on Corticosteroids - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on Corticosteroids - Year-over-year growth 2021-2026 (%)

• 5.4 Monoclonal antibodies - Market size and forecast 2021-2026 
• Exhibit 32: Chart on Monoclonal antibodies - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Monoclonal antibodies - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Monoclonal antibodies - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Monoclonal antibodies - Year-over-year growth 2021-2026 (%)

• 5.5 Others - Market size and forecast 2021-2026
• Exhibit 36: Chart on Others - Market size and forecast 2021-2026 ($ million)
• Exhibit 37: Data Table on Others - Market size and forecast 2021-2026 ($ million)
• Exhibit 38: Chart on Others - Year-over-year growth 2021-2026 (%)
• Exhibit 39: Data Table on Others - Year-over-year growth 2021-2026 (%)

• 5.6 Market opportunity by Product 
• Exhibit 40: Market opportunity by Product ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview 
• Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation 
• Exhibit 42: Chart on Market share by geography 2021-2026 (%)
• Exhibit 43: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison 
• Exhibit 44: Chart on Geographic comparison
• Exhibit 45: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026 
• Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Germany - Market size and forecast 2021-2026
• Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%)

• 7.9 Canada - Market size and forecast 2021-2026
• Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.10 UK - Market size and forecast 2021-2026
• Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.11 China - Market size and forecast 2021-2026
• Exhibit 78: Chart on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 79: Data Table on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 80: Chart on China - Year-over-year growth 2021-2026 (%)
• Exhibit 81: Data Table on China - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography 
• Exhibit 82: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges 
• Exhibit 83: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape 
• Exhibit 84: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption 
• Exhibit 85: Overview on factors of disruption

• 9.4 Industry risks 
• Exhibit 86: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered 
• Exhibit 87: Vendors covered

• 10.2 Market positioning of vendors 
• Exhibit 88: Matrix on vendor position and classification

• 10.3 AstraZeneca Plc 
• Exhibit 89: AstraZeneca Plc - Overview
• Exhibit 90: AstraZeneca Plc - Product / Service
• Exhibit 91: AstraZeneca Plc - Key news
• Exhibit 92: AstraZeneca Plc - Key offerings

• 10.4 Amneal Pharmaceuticals Inc. 
• Exhibit 93: Amneal Pharmaceuticals Inc. - Overview
• Exhibit 94: Amneal Pharmaceuticals Inc. - Business segments
• Exhibit 95: Amneal Pharmaceuticals Inc. - Key news
• Exhibit 96: Amneal Pharmaceuticals Inc. - Key offerings
• Exhibit 97: Amneal Pharmaceuticals Inc. - Segment focus

• 10.5 Baxter International Inc. 
• Exhibit 98: Baxter International Inc. - Overview
• Exhibit 99: Baxter International Inc. - Business segments
• Exhibit 100: Baxter International Inc. - Key news
• Exhibit 101: Baxter International Inc. - Key offerings
• Exhibit 102: Baxter International Inc. - Segment focus

• 10.6 Concord Biotech Ltd. 
• Exhibit 103: Concord Biotech Ltd. - Overview
• Exhibit 104: Concord Biotech Ltd. - Product / Service
• Exhibit 105: Concord Biotech Ltd. - Key offerings

• 10.7 F. Hoffmann La Roche Ltd. 
• Exhibit 106: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 107: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 108: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 109: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 110: F. Hoffmann La Roche Ltd. - Segment focus

• 10.8 Incyte Corp. 
• Exhibit 111: Incyte Corp. - Overview
• Exhibit 112: Incyte Corp. - Business segments
• Exhibit 113: Incyte Corp. - Key offerings
• Exhibit 114: Incyte Corp. - Segment focus

• 10.9 Kezar Life Sciences Inc. 
• Exhibit 115: Kezar Life Sciences Inc. - Overview
• Exhibit 116: Kezar Life Sciences Inc. - Product / Service
• Exhibit 117: Kezar Life Sciences Inc. - Key news
• Exhibit 118: Kezar Life Sciences Inc. - Key offerings

• 10.10 Rigel Pharmaceuticals Inc. 
• Exhibit 119: Rigel Pharmaceuticals Inc. - Overview
• Exhibit 120: Rigel Pharmaceuticals Inc. - Product / Service
• Exhibit 121: Rigel Pharmaceuticals Inc. - Key offerings

• 10.11 Sanofi SA 
• Exhibit 122: Sanofi SA - Overview
• Exhibit 123: Sanofi SA - Business segments
• Exhibit 124: Sanofi SA - Key news
• Exhibit 125: Sanofi SA - Key offerings
• Exhibit 126: Sanofi SA - Segment focus

• 10.12 Teva Pharmaceutical Industries Ltd. 
• Exhibit 127: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 128: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 129: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 130: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 131: Teva Pharmaceutical Industries Ltd. - Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist 
• Exhibit 132: Inclusions checklist
• Exhibit 133: Exclusions checklist

• 11.3 Currency conversion rates for US$ 
• Exhibit 134: Currency conversion rates for US$

• 11.4 Research methodology 
• Exhibit 135: Research methodology
• Exhibit 136: Validation techniques employed for market sizing
• Exhibit 137: Information sources

• 11.5 List of abbreviations 
• Exhibit 138: List of abbreviations

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio